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Airway smooth muscle constriction induced by cholinergic agonists such as methacholine (MCh), which is typically increased in
asthmatic patients, is regulated mainly by muscle muscarinic M3 receptors and negatively by vagal muscarinic M2 receptors. Here
we evaluated basal (intrinsic) and allergen-induced (extrinsic) airway responses to MCh. We used two mouse lines selected to
respond maximally (AIRmax) or minimally (AIRmin) to innate inflammatory stimuli. We found that in basal condition AIRmin
mice responded more vigorously to MCh than AIRmax. Treatment with a specific M2 antagonist increased airway response of
AIRmax but not of AIRmin mice. The expression of M2 receptors in the lung was significantly lower in AIRmin compared to
AIRmax animals. AIRmax mice developed a more intense allergic inflammation than AIRmin, and both allergic mouse lines
increased airway responses to MCh. However, gallamine treatment of allergic groups did not affect the responses to MCh. Our
results confirm that low or dysfunctional M2 receptor activity is associated with increased airway responsiveness to MCh and
that this trait was inherited during the selective breeding of AIRmin mice and was acquired by AIRmax mice during allergic lung
inflammation.
1. Introduction
The cholinergic system plays a role in the regulation of
many pathophysiological mechanisms. In the lung, the vagal
parasympathetic nervous system via muscarinic receptors
represents the dominant autonomic control of airway smooth
muscle tone. Acetylcholine released at neuromuscular junc-
tions binds toM3muscarinic receptors in the smoothmuscle
and promotes airway contraction through a number of well-
defined intracellular signaling mechanisms [1, 2]. An impor-
tant negative feedback mechanism is given by the neuronal
M2 muscarinic receptor that inhibits acetylcholine release
[3, 4]. Airway hyperresponsiveness (AHR) is an exaggerated
smooth muscle constriction observed in certain individuals
among a population, which can occur in response to a
variety of stimuli such as histamine, exercise, cold air, and
methacholine (MCh). AHR is a cardinal feature of asthma
[5]. Although there are exceptions [6], studies in asthmatic
patients indicate a positive correlation between AHR and
allergic eosinophilic inflammation [7]. Accordingly, suscepti-
bility to develop asthma is associatedwith IL-5, a key cytokine
for eosinophil differentiation, activation, and survival [8, 9].
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One of the proposedmechanisms for allergic AHR toMCh is
loss of function of vagal M2 receptors caused by eosinophilic
inflammation [10–14]. Indeed, blockage of M2 receptors
results in an increased acetylcholine release from vagal nerve
endings that ultimately enhances bronchoconstriction [4, 15].
In this sense, AHR can be viewed as an integrated immune-
neural circuit. Another well-established immune-mediated
neural circuit is the cholinergic anti-inflammatory pathway
[16–18]. This efferent pathway is triggered by proinflam-
matory cytokines via afferent sensory neurons and culmi-
nates in the release of acetylcholine by the vagus nerve. In
turn, acetylcholine signals thorough nicotine acetylcholine
receptor subunit 𝛼7 (𝛼7nAChR), expressed on immune cells,
inhibiting proinflammatory cytokine production [19].
Because the cholinergic system is involved in bron-
choconstriction as well as regulation of inflammation, the
present study aimed to evaluate the airway responses toMCh
and airway allergic responses in two mouse lines selected to
respond maximally (AIRmax) or minimally (AIRmin) to an
innate inflammatory stimuli [20], focusingmainly on the role
of M2 receptors. These mouse lines were produced by bidi-
rectional selective breeding from a genetically heterogeneous
population and behave differently in several experimental
models such as arthritis [21], lung cancer [22], and bacterial
infection [23]. Here we evaluated whether an innate response
that selected the gene combinations determining AIRmax
and AIRmin phenotypes would affect basal (intrinsic) or
allergic (extrinsic) airway responses to MCh as well as an
immune-adaptive T-helper-type-2- (Th2-) mediated stimuli
in an experimental model of lung eosinophilic inflammation.
2. Results
2.1. Respiratory Pattern and Expression of M2 and M3
Muscarinic Receptors. It was previously reported that the
basal airway responsiveness varies markedly among inbred
strains of mice [24, 25]. Indeed, under basal noninflamma-
tory condition multiple quantitative trait loci linked to AHR
were identified in inbred mice strains [26, 27]. Therefore,
we first determined the basal respiratory pattern of AIRmin
and AIRmax in response to increasing doses of MCh in
conscious unrestrained mice using a noninvasive whole-
body barometric plethysmography. AIRmin mice showed a
marked increase in Penh values when compared to AIRmax
mice (Figure 1(a)).The dose of MCh required to elicit a 200%
increase over baseline values (PC200) was 2.5-fold higher in
AIRmax than in AIR min (Figure 1(b)). Our results indicate
that the genetic selective process markedly influenced airway
response to MCh. In this context, AIRmin animals can be
considered as hyperresponsive whereas AIRmax animals are
hyporresponsive to MCh.
The contractile response of airway smooth muscles to
muscarinic agonists is inducedmainly by activation ofmuscle
M3 receptor subtype and inhibited by activation of vagal
M2 receptor subtype. Thus, we determined the expression
of M3 and M2 muscarinic receptors in lung tissue. We
found that M3 receptor expression was lower in AIRmin
than in AIRmax animals, as revealed by real-time PCR and
Western blot analysis (Figures 1(c)-1(d)), thus, it could not
explain the hyperresponsiveness of AIRmin mice to MCh.
Therefore, we evaluated M2 muscarinic receptor expression
by PCR and Western blot analyses. M2 receptor expression
was lower in AIRmin than in AIRmax mice (Figures 1(e)-
1(f)). Altogether, these results indicate that low expression of
muscarinic M2 receptor in AIRminmice might be associated
with the increased AHR to MCh observed in these animals.
2.2. In Vivo M2 Muscarinic Receptor Activity. To evaluate
the role of M2 receptor subtype on the airway responses in
vivo, we treated the animals with gallamine, a selective M2
receptor antagonist. Gallamine treatment increased signifi-
cantly Penh values in AIRmax but not in AIRmin mice when
compared with untreated mice (Figures 2(a)-2(b)). However,
gallamine treatment increased the responses to MCh in
AIRmin animals indicating some activity of M2 receptor,
but this activity was not sufficient to generate statistically
significant data when compared to untreated group. In our
study, we only used one dose of gallamine based on a previous
report [28]. Taken together, these results indicate that the
negativemodulatory effect exerted by vagalM2 receptors was
present in AIRmax mice but minimally in AIRmin animals.
Therefore, the robust response to MCh observed in AIRmin
mice and the lack of significant effect of gallamine indicate
dysfunctional vagal M2 activity in this mouse line.
2.3. ExVivoM2ReceptorActivity. Theresults obtained in vivo
with the noninvasive method indicated a major role of vagal
M2 receptors in inhibiting airway constriction. In order to
determine the role of muscle M2 receptors, we evaluated ex
vivo the effect of gallamineonsmooth muscle constriction to
MCh in isolated trachea. In this scenario, vagal receptors are
excluded, and only muscarinic receptors of airway smooth
muscle responded to MCh. We found that tracheal smooth
muscle constriction induced by MCh was more intense in
AIRmaxwhen compared with AIRmin animals (Figure 3(a)).
Gallamine treatment did not affect tracheal smooth muscle
constriction induced by MCh (Figures 3(b)-3(c)), indicating
that muscle M2 receptors have no role in smooth muscle
contraction induced by MCh.
2.4. Allergic Lung Inflammation and Expression of Muscarinic
Receptors. Loss of M2 receptor function due to allergic
inflammation has been well documented [29, 30]. It has
been shown that eosinophilic major basic protein plays a
key role in M2 receptor dysfunction (for review see [10]).
We first determined the magnitude of allergic inflammation
developed in AIRmin and AIRmax mice referred as OVA
group. Figure 4 shows that allergic lung inflammation, as
revealed by total number of inflammatory cells (Figure 4(a))
and eosinophils (Figure 4(b)) in BAL, was more intense in
AIRmax than in AIRmin animals. Accordingly, the levels of
Th2 cytokines (IL-4 and IL-13) and mucus production were
higher in AIRmax than in AIRmin mice (Figures 4(c)–4(e)).
Histological analysis confirmed the more intense allergic
inflammation in AIRmax when compared with AIRmin
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Figure 1: Respiratory pattern and expression of muscarinic receptors in AIRmin and AIRmax mice. Respiratory pattern was determined
in awake, unrestrained mice by noninvasive whole-body barometric plethysmography. (a) Penh values were used as an index of
bronchoconstriction induced after sequential delivery of increasing concentrations of MCh (3, 6, 12, and 25mg/mL) and (b) provocative
concentration of aerosol MCh at a 200% increase (PC200) over baseline values. Gene (c and e) or protein (d and f) expression of M2 andM3
muscarinic receptors was evaluated by real-time PCR orWestern blot analysis in lungs from AIRmin and AIRmax mice. Real-time PCR was
carried out using 𝛽-actin gene expression as internal control for normalization of M3R (c) and M2R (e) mRNA transcription levels. All PCR
reactions were quantitative reactions made by real-time PCR. InWestern blot analysis the density of M3R (d) andM2R (f) protein expression
was nor aerosol at a malized to actin expression in each sample. Western blots were quantified by densitometry using the ImageJ software
(NIH). Real-time PCR andWestern-blot analyses were performed using pooled lungs from 5mice. Data are expressed as mean ± SEM of five
mice per group and are representative of three experiments; ∗𝑃 < 0.05.
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Figure 2: Respiratory pattern and airway resistance of AIRmin and
AIRmax mice in the presence or absence of gallamine, a specific
M2 receptor antagonist. Respiratory pattern to inhaled MCh was
measured using noninvasive method in AIRmin (a) and AIRmax
(b) mice. Airway resistance was measured by invasive method in
AIRmin (c) and AIRmax (b) mice. Measurements were performed
in the presence (black symbols) or absence (open symbols) of
gallamine, in response to increasing concentrations ofMCh. Results
are reported as Penh values (a-b). Penh data represent the means
± SEM of five mice per group and are representative of three
experiments (unpaired 𝑡-test, ∗𝑃 < 0, 05 as compared to PBS group).
mice as shown by peribronchovascular cellular infiltrate and
increased mucus (Figure 4(f)).
We next determined the respiratory pattern of allergic
AIRmin and AIRmax animals in the absence or presence
of gallamine. Firstly, we found that allergic AIRmin and
AIRmax mice showed higher Penh values when compared
with control mice (Figures 5(a)-5(b)). Statistical analysis
performed on data, represented by area under the curve,
confirmed that the responses to MCh were significantly
increased in allergic mice when compared with control non-
allergic mice (Figures 5(c) and 5(d)). However, no significant
differences were observed in Penh values of allergic mice
treated or not with gallamine (Figures 5(a)–5(d)).
Because allergic mice showed an enhanced response
to MCh when compared with control mice and gallamine
treatment was ineffective in increasing Penh values, we
asked whether the expression of muscarinic receptors has
changed during allergic inflammation.We found that allergic
inflammation did not change the expression of M2 or M3
receptors (Figures 5(e)–5(h)). Altogether, these data suggest
thatM2muscarinic receptors dysfunction rather than altered
muscarinic expressionmight be responsible for the increased
response to MCh observed in allergic AIRmax or AIRmin
mice.
3. Discussion
Our work shows that AIRmin and AIRmax mouse lines
represent a model to study lung muscarinic receptor func-
tions and its relation with the development of an allergic
lung disease. The main cholinergic pathways are depicted
in Figure 6. We found that AIRmin and AIRmax animals
develop different patterns of airway reactivity under basal
or inflammatory conditions. Notably, respiratory responses
to increasing doses of MCh observed in AIRmin mice in
basal condition were significantly higher than that obtained
in AIRmax animals. Previous studies identified multiple
quantitative trait loci (QTL) linked to basal, noninflamma-
tory airway hyperreactivity in specific inbred mouse strains
[26, 27, 31]. It was found in A/J mice that the enhanced
baseline airway reactivity was independent of lymphocytes or
bone marrow-derived cells [32]. Airway responses to MCh
are regulated by muscarinic M3 receptor present on muscle
cells, which induces muscle constriction, and negatively
regulated by the activation of muscarinic M2 receptors on
vagal nerve endings, which reduce acetylcholine release at
the neuromuscular junction [2, 3, 33, 34]. Here we present
evidence that enhanced basal (intrinsic) airway reactivity
of AIRmin mice is associated with the low expression and
activity of M2 receptors. This assumption is based on the
following findings: firstly, mRNA and protein expression of
M2 receptors were decreased in AIRmin mice compared
to AIRmax animals; secondly, although mRNA and protein
expression of M3 receptors, the major muscarinic pathway
for airway smooth muscle constriction, were increased in
AIRmax mice, these animals did not show enhanced basal
airway reactivity; thirdly, the use of gallamine, a selective
M2 receptor antagonist significantly increased the airway
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Figure 3: Tracheal responsiveness to MCh in AIRmin or AIRmax mice. Tracheal responsiveness of AIRmin or AIRmax to inhaled MCh was
evaluated in the absence (a) or presence (b and c) of gallamine. Mouse tracheal segments were cultured in PBS or with gallamine for 20min.
Thereafter, the segments were maintained in the organ bath, and the contractile responses toMChwere recorded. Data are expressed as mean
± SEM of six mice per group ∗𝑃 < 0.05.
responses of AIRmax mice, but affected minimally the
responses of AIRmin mice. These results indicated that
gallamine treatment impaired M2 function in AIRmax but
not in AIRmin mice. Importantly, in conditions where the
participation of vagal M2 receptors were precluded such
as in ex vivo experiments with isolated tracheal rings, the
tracheal responsiveness of AIRmin mice to MCh was not
affected by gallamine treatment, reinforcing the predominant
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Figure 4: Allergic lung inflammation in AIRmin and AIRmax mice. AIRmin or AIRmax mice were sensitized twice (s.c.) with ovalbumin
adsorbed on alum and challenged twice with ovalbumin (i.n.) (OVA group). Control group consisted of nonmanipulated animals. The
experiments were performed 24 h after the last OVA challenge. The total inflammatory cells numbers (a), the number of eosinophils (b),
and the levels of cytokines IL-5 (c) and IL-13 (d) were determined in bronchoalveolar lavage (BAL) fluid.Themucus index was determined by
histocytometry of lung sections stained with periodic acid-Schiff (e) representative lung micrographs stained with HE of control and allergic
AIRmin or AIRmax mice (original magnification ×200) (f). Data are expressed as mean ± SEM of four mice per group and are representative
of two experiments; Statistical analyses of Student’s 𝑡-test for (a), (b), (c), and (d). Statistical analyses of MannWhitney-test for (e). ∗𝑃 < 0.05
relative to control group. #𝑃 < 0.05 relative to AIRmin mice.
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Figure 5: Continued.
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Figure 5: Pulmonary muscarinic receptors function and expression in allergic AIRmin and AIRmax mice. AIRmin or AIRmax mice were
sensitized and challenged with OVA as in Figure 4. Control group consisted of nonmanipulated animals. The experiments were performed
24 h after the last OVA challenge. Respiratory pattern of allergic AIRmin (a and c) or AIRmax (b and d) to inhaled MCh was evaluated in the
presence or absence of gallamine. Penh values were used as an index of bronchoconstriction induced after sequential delivery of increasing
concentrations of MCh. Area under the curve was obtained from Penh values (c and d). Gene (e and g) or protein (f and h) expression of
the M2 and M3 muscarinic receptors was evaluated by real-time PCR or Western blot analysis in lungs from OVA-sensitized AIRmin and
AIRmax mice. The real-time PCR was carried out using 𝛽-actin gene expression as internal control for normalization of M3R (e) and M2R
(g) mRNA transcription levels. In Western blot analysis the density of M3R (f) and M2R (h) protein expression was normalized to actin
expression in each sample. Data are expressed as mean ± SEM of four mice per group and are representative of two experiments. Western
blots data were quantified by densitometry using the ImageJ software (NIH). Statistical analyses of Student’s 𝑡 test for (a), (b), (e), (f), (g), and
(h). Statistical analyses of ANOVA following Tukey HSD for (c) and (d). ∗𝑃 < 0.05 relative to control group; NS, not significant.
role of M3 receptors in smooth muscle constriction. Our
ex vivo experiments with tracheal rings are in line with
previous studies in M2 receptor KOmice, which showed that
M2 receptors do not exert an inhibitory effect on tracheal
constriction induced by cholinergic stimuli [35, 36]. Several
studies have shown that the loss of M2 receptor function
increases acetylcholine release and potentates vagally medi-
ated bronchoconstriction (reviewed in [15]). Similar to our
findings, experiments performed with estrogen receptor-𝛼
KOmice showed enhanced airway responsiveness to inhaled
MCh and serotonin under basal conditions and this was
associatedwith reducedM2 receptor expression and function
[28, 36]. In addition, our results are in line with the work of
Fisher et al. showing that M2-deficient (KO) mice display a
significantly enhanced in vivo bronchoconstrictor response
to vagal stimulation [37].
In allergic conditions, AIRmin andAIRmaxmice showed
a significant increase over baseline response (control group)
in Penh value. The change in respiratory pattern of AIRmax
animals after allergic inflammation could not be attributed
to increased expression of M3 receptors. Because gallamine
treatment had no effect, we favor the notion that the
major mechanism for the increased respiratory responses
of allergic AIRmax mice was due to decreased expression
and/or dysfunctionM2 receptor.This finding is in accordance
with previous studies in allergic mice or asthmatic patients
indicating that M2 receptor dysfunction rather than M3
receptor overexpression is associated with airway hyperre-
activity (reviewed in [3, 4, 33]). It was shown by Ricci et al.
(2002, 2008) that patients with asthma or rhinitis present
different expression M2 and M3 receptors on lymphocytes,
but the role of these receptors in these cells is still elusive
[38, 39].
A striking difference between AIRmin and AIRmax
animals was related to the intensity of T-helper-type-2-
cells- (Th2-) mediated allergic responses such as eosinophilic
inflammation, type 2 cytokines production, and mucus pro-
duction that were all significantly higher in AIRmax when
compared with AIRmin animals. It is known that inflam-
matory mediators play a role in enhancing bronchocon-
striction by several pathways. The major basic protein from
eosinophils can bind directly to M2 receptors, blocking the
interaction with acetylcholine that leads to a higher release
of acetylcholine in airway smooth muscles [10]. In addition,
type 2 cytokines play a critical role in the development of
bronchial responsiveness. IL-13, for instance, may increase
bronchoconstriction by directly modulating smooth muscle
contractibility and promoting airway hyperreactivity through
multiple molecular mechanisms [40, 41]. The participation
of these signaling pathways in our asthma murine model in
AIRmin and AIRmax animals remains to be determined.
Interestingly, AIRmin and AIRmax mice that were
selected by an innate stimuli maintained the polarized
inflammatory profile with a stimulus derived from T-cell-
dependent adaptive inflammation. We speculate that the
enhanced Th2 responses of AIRmax animals was due to an
enhanced production of inflammatory cells in bone marrow,
as shown previously for neutrophils [42].
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Figure 6: A model illustrating cholinergic receptors on pulmonary
parasympathetic nerves and airway smooth muscle. Acetylcholine
(ACh) released at parasympathetic ganglion binds to nicotinic
(N1) and muscarinic (M1) receptors and activates postganglionic
cholinergic nerve to release ACh at neuromuscular junction. ACh
at neuromuscular junctions binds to M3 receptors in the airway
smooth muscle, inducing muscle contraction, and to the autoin-
hibitory M2 receptors located in the vagus nerve, that limits ACh
release at the neuromuscular junction and decreasing smooth
muscle constriction.
How M2 receptors could be associated with two con-
trasting situations? On one side, M2 dysfunction was asso-
ciated with AIRmin animals that have been selected for low
inflammatory response and on the other side with AIRmax
animals that develop an intense allergic inflammation. These
apparently conflicting findings can be reconciled by consider-
ing that acetylcholine can also regulate inflammation via the
nicotinic acetylcholine receptor subunit alpha7 (𝛼7nAchR)
known as the “cholinergic anti-inflammatory pathway” [16,
17, 43, 44]. It follows that cholinergic anti-inflammatory path-
way would favor the selective process of AIRmin animals.
The 𝛼7nAchR is coded by Chrna7 gene, which is mapped
closed to inflammatory response modulator 1 (Irm1) locus
on chromosome 7 [45]. The Irm1 locus region contains about
230 known genes that are involved in inflammatory response
regulation [45]. Interestingly, AIRmin mice present the same
Imr1 locus haplotype as A/J MCh hyperresponsive mice. The
genotype of AIRmin at the rs32017050 (SNP at the peak of the
Irm1 locus) is “TT” similar to A/J mice, which is one of the 8
parental strains used in F0 population of those selected mice.
On the other hand, AIRmaxmice are “CC”, showing identical
genotypes of C57BL/6J, CBA/J, DBA/2J, P/J, and SWR/J mice
(mouse genomic informatics) that are hyporesponsive to
MCh.Thus, M2 receptor dysfunction in AIRmin animals can
be viewed as an additional mechanism inherited during the
selective process that contributed for the low inflammatory
phenotype. In the same vein, the loss ofM2 receptor function
observed in AIRmax animals during allergic inflammation
could be interpreted as a neural homeostatic mechanism of
the organism to control allergic inflammation [46]. Overall,
the neuronal circuits that operate in inflammation or allergic
asthma can be viewed as homeostatic mechanisms to coun-
terbalance the inflammatory process.
Since asthma is a complex syndrome, the AIRmin/AIR-
max model might mirror clinical cases where airway reactiv-
ity is more prominent than airway inflammation as described
in fatal asthma and in clinical conditions where airway
inflammation is more robust than airway reactivity [47].
4. Material and Methods
4.1. Mice. The AIRmax and AIRmin original mice were
obtained by bidirectional selective breeding starting from
a high polymorphic population produced by intercross
between eight inbredmouse strains (A, DBA-2, P, SWR, CBA,
SJL, BALB/c, and C57Bl/6) [20]. The selective breeding of
these animals for maximal or minimal acute inflammatory
response was based on both cellular infiltrate and protein
contents in the inflammatory exudate 24 h after subcutaneous
implant of polyacrylamide beads (Biogel). The main inter-
line difference was characterized by the strong differential
neutrophil PMN count in inflammatory exudate. Several
quantitative trait loci (QTL) were recently detected in these
mouse lines [46, 48]. Animals were obtained and maintained
at the animal facilities of the Immunogenetics Laboratory
at Butantan Institute on standard pellet food and water
ad libitum. All experiments were performed following the
guidelines for animal use approved by the Ethics Committee
in Animal Experimentation of the University of Sa˜o Paulo,
Brazil, which is in accordance with the Ethical Principals of
the Brazilian College of Animal Experimentation (COBEA),
ethics protocol number 26, page 30, Book 2, ICB, USP.
4.2. Ovalbumin (OVA) Sensitization and Challenge. Mice
were sensitized and boosted subcutaneously (s.c.) with 4𝜇g
of chicken OVA (Sigma-Aldrich, St. Louis, MO, USA) and
1.6mg of aluminum hydroxide gel in 0.2mL of sterile PBS on
days 0 and 7. Removal of lipopolysaccharides from OVA was
performed as previously described [49]. After LPS removal,
the endotoxin level of OVA was below the limit of detection
in the LAL (Limulus amoebocyte lysate) assay (QCL-1000
kit, BioWhittaker, Walkersville, MD, USA). Airway inflam-
mation was induced by two intranasal (i.n.) challenges with
10 𝜇gOVAon days 14 and 21, animals were anaesthetizedwith
ketamine (50mg/kg body weight) and xilazine (20mg/kg
body weight) intraperitoneally in 200𝜇L of PBS for intra-
nasal instilations. Experiments were performed 24 h after the
last i.n. OVA challenge, on day 22.
4.3. Airway Responsiveness to Methacholine by Noninvasive
Barometric Plethysmography. Respiratory parameters were
determined before and after administration of increasing
doses of inhaledMCh (3, 6, 12, and 25mg/mL) by noninvasive
method in conscious unrestrained mice using whole-body
plethysmograph (Buxco Electronics Inc. Wilmington, North
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Carolina, USA), as previously described [50, 51]. Signals
were analyzed using BioSystem XA software to derive whole-
body flow parameters including respiratory frequency, tidal
volume, minute ventilation, peak inspiratory flow, peak
expiratory flow, and enhanced pause (Penh). Penh is a dimen-
sionless value that takes into account box pressure recorded
during inspiration and expiration and the timing comparison
of early and late expiration, which was used to define the
breathing pattern. Linear interpolationwas used to determine
the provocative concentration of MCh aerosol at which a
200% increase (PC200) over baseline values was observed for
Penh values. To test M2 muscarinic receptor function, mice
were exposed or not to M2 muscarinic receptor antagonist
gallamine (30𝜇M/animal) [28], nebulized 30 minutes before
recording of respiratory parameters.
4.4. Ex Vivo Trachea Responsiveness to Methacholine. To test
M2 muscarinic receptor function, rings of tracheal tissue
were removed and mounted using two steel hooks in a
15mL organ bath for the measurement of isometric force
contraction [47] in presence or absence of theM2muscarinic
receptor antagonist gallamine (30 𝜇M), added 20 minutes
before administration of MCh. The force contraction was
determined using a force displacement transducer and a chart
recorder (Powerlab Labchart, AD Instruments, Colorado
Springs, CO, USA). The tracheal tissue was maintained in
an organ bath filled with Krebs-Hanseleit (KH) buffer at
37∘C continuously aerated (95% O
2
and 5% CO
2
) for 40min
(equilibrium period). After this period, the tracheal tension
was adjusted to 0.5 g, and the tissue viability was assessed
by replacing KH solution with KCl buffer (60mM). The
cumulative dose-response curve to MCh was constructed
according to Van Rossum (1963) [52].
4.5. Bronchoalveolar Lavage Fluid. Mice were deeply anaes-
thetized by intraperitoneal injection of xilazine (50mg/kg
body weight) and ketamine (100mg/kg body weight),
folowed by cervical dislocation. Blood samples from the
retro-orbital plexus were collected for serum antibody deter-
minations. The trachea was cannulated, and lungs were
washed twice with 0.5 and 1.0mL PBS, respectively. Total
and differential cell counts of bronchoalveolar lavage (BAL)
fluid were determined by haemocytometer and cytospin
preparation stained with Instant-Prov, hematoxylyn-eosin
(Newprov, Pinhais, PR, Brazil).
4.6. Cytokines Measurements. The levels of cytokines (IL-
5 and IL-13) in the BAL fluid were assayed by sand-
wich kit ELISA according to the manufacturer’s instruction
(PharMingen, San Diego, CA, USA), as previously described
[53]. For IL-13 determinations, the pair used was 38 213.11 and
biotinylated goat polyclonal anti-IL-13 from R&D Systems
(Minneapolis, MN, USA). Values were expressed as pg/mL
deduced from standards that run in parallel with recombi-
nant cytokines. The limit of detection was 10 pg/mL for IL-5
and 31 pg/mL for IL-13.
4.7. Histological Analyses. After BAL collection, lungs were
perfused via the right ventricle with 10mL of PBS to
remove residual blood, then immersed in 10% phosphate-
buffered formalin for 24 h, and in 70% ethanol until embed-
ded in paraffin. Lung sections with 5 𝜇m were stained
with hematoxylin/eosin for evaluation of peribronchial and
perivascular lung inflammation or with periodic acid-Schiff
(PAS)/haematoxylin for the evaluation of mucus production,
as previously described [51]. Briefly, a quantitative digital
morphometric analysis was performed using the application
program Metamorph 6.0 (Universal Images Corporation,
Downingtown, PA, USA).The circumference area of bronchi
and the PAS-stained area were electronically measured, and
the mucus index was determined by the following formula:
(PAS-stained area/bronchial circumference area) × 100.
4.8. Western-Blot Assays. Lungs from mice were homoge-
nized in ice-cold lysis buffer containing protease inhibitors,
10mM TrisHCl (pH 7.5), 8M urea, 20mM EDTA, 150mM
NaCl, and 1% Triton X-100. Membrane proteins (40 𝜇g)
were fractionated by differential centrifugation, separated
by SDS-PAGE and transferred to nitrocellulose membranes.
The incubation procedure was performed using primary
and secondary antibodies, as previously described [54–57].
The following polyclonal rabbit antisera were used: anti-M1
(1 : 200), anti-M2 (1 : 100), anti-M3 (1 : 100), and anti-𝛽-actin
(1 : 400) (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
𝛽-actin protein expression was used as an internal standard
for relative quantification of muscarinic receptors expression
levels. Western blots were quantified by densitometry using
the ImageJ software (NIH, Washington DC, USA).
4.9. RNA Isolation, Reverse Transcription, Real-Time PCR,
and Conventional-PCR. Total RNA was isolated using Trizol
(Invitrogen, Carlsbad, CA, USA)) from lungs of nonmanip-
ulated AIRmax and AIRmin mice. Integrity of the isolated
RNA was verified by separation of an aliquot of the extracted
RNA on a 2% ethidium bromide-stained agarose gel. DNA
was removed from RNA samples by incubation with DNase I
(Ambion Inc., Austin, TX, USA).
Total RNA (3 𝜇g) was reversely transcribed to cDNAwith
200U of RevertAid H Minus M-MuLV-reverse transcriptase
(Fermentas Inc., Hanover, MD, USA). DNA templates were
amplified by real-time PCR on the 7000 Sequence Detec-
tion System (ABI Prism, Applied Biosystems, Foster City,
CA,USA) using the Sybr green method [54, 56] or were
amplified by PCR and analyzed as described previously [54,
56]. Variations in cDNA concentrations were normalized
with 𝛽-actin as an internal control, which is a constitutively
expressed gene. Experiments were performed in triplicate for
each data point. Primer sequences for reverse transcription
and quantitative PCR amplification (qRT-PCR) of mRNA
used in this study were 𝛽-actin FWD ctg gcc tca ctg tcc acc
tt, REV cgg act cat cgt act cct gct t; M2 mAChR FWD gct gcg
tgg gtt ctt tcc t, REV ccc cta cga tga act gcc ag; M3 mAChR
FWD cca tct ggc aag tgg tct tc, REV tgc cac aat gac aag gat
gtt g. Negative controls were conducted on water and on total
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RNA. All PCR reactions were quantitative reactions, made by
real-time PCR.
4.10. Statistical Analysis. Statistical analyses were performed
employing JMP 9.0 (JMP SAS Institute Inc). Results are
expressed as mean ± SEM. Continuous variables were log-
transformed for the analyses when the normality of the
distribution was rejected by the Shapiro-Wilk 𝑊 test. For
comparisons between two groups, normality was tested and
then data were submitted to Student’s 𝑡-test. For comparisons
amongst 3 or more groups it was used ANOVA following
In the case of absence of normality, even in log-transformed
variables, Mann-Whitney was used for comparisons between
2 groups and or Kruskal-Wallis tests for three ormore groups.
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